Stem Cells Transplant Institute provides stem cell therapy for Parkinson’s disease as part of a personalized regenerative medicine approach focused on supporting neurological function, mobility, and daily activities
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement and coordination. It occurs when the nerve cells in the brain that produce dopamine – a chemical messenger essential for smooth, controlled movement – gradually deteriorate.
As dopamine levels decline, individuals may experience tremors, stiffness, slowed movement, and changes in balance or coordination.
According to the Parkinson’s Foundation (2023), nearly 10 million people worldwide (approximately 1% of the population over the age of 65) are living with Parkinson’s disease, making it the second most common neurodegenerative condition after Alzheimer’s disease.
Stem cell therapy offers an innovative, complementary approach that may help support brain health and neurological function.
The Stem Cells Transplant Institute in Costa Rica offers a science-based regenerative option seeking to complement standard neurologic management for Parkinson’s disease. Our therapies are delivered in San José within a facility that operates under strict clinical and safety protocols.
Living with Parkinson’s often means navigating a medication regimen that becomes harder to manage as the disease progresses. While pharmacologic therapy and neurologic care remain the cornerstone of management, some individuals seek additional investigational approaches that may complement their existing treatment plan.
Patients from the United States, Canada, and Europe frequently travel to San José to access regenerative medicine programs within specialized clinical environments. In addition, MSC therapy in Costa Rica costs a fraction of what equivalent private programs run in North America. Direct flights from most U.S. cities are under five hours long, and our clinical team is experienced in coordinating travel details with caregivers who make the trip alongside patients.
Before any Parkinson’s patient travels, our physicians review disease stage, motor and non-motor symptom profile, and current medications in detail to determine candidacy. Nothing about the protocol is standard — it is built around where each patient actually is in their progression.
Current research is exploring how mesenchymal stem cells (MSCs) may support neurological health in people living with Parkinson’s disease.
Early studies suggest that MSCs can release a variety of trophic and immunomodulatory factors that may help modulate inflammation associated with neurodegeneration, support cellular survival pathways in dopamine-related neural circuits and promote a healthier environment for neural communication.
While stem cell therapy is not a cure, research is exploring its potential to support neurological function and overall wellbeing.
(Evidence remains preliminary and ongoing clinical trials are required to confirm these effects.)
MSCs have shown in laboratory and animal studies to release signaling molecules (cytokines and growth factors) that may help regulate inflammatory activity in areas of the brain affected by Parkinson’s disease.
(Source: Frontiers in Neurology, 2022)
MSCs can secrete helpful, naturally-occurring proteins—such as BDNF (brain-derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor), which are known to play roles in the survival of dopaminergic neurons. These proteins act like “support signals” that help protect the brain’s dopamine-producing nerve cells and may help support cellular survival pathways.
(Source: Stem Cell Research & Therapy, 2023)
MSCs may help rebalance overactive immune activity, potentially reducing processes that contribute to ongoing neurodegeneration.
(Cell Transplantation, 2021)
Stem cell signaling promotes synaptic plasticity and communication between brain regions, potentially improving coordination and movement control.
(Neuroscience Letters, 2022)
Although individual responses vary widely, published studies and clinical observations have reported potential supportive improvement in the following functional domains:
*These percentages summarize ranges reported in selected clinical studies and observational cohorts under controlled conditions and standardized outcomes measures. They are not specific to any single study or to treatments performed at Stem Cells Transplant Institute. They should not be interpreted as averages, promises, or guaranteed results for individual patients. Evidence for MSC therapy in Parkinson’s disease remains preliminary, and ongoing controlled clinical trials are still evaluating the magnitude, durability and consistency of these effects. All observations should be considered exploratory and hypothesis-generating rather than definitive proofs of efficacy.
Published studies and patient-reported outcomes suggest that improvements following mesenchymal stem cell therapy for Parkinson’s disease may develop gradually over time. These timelines are illustrative summaries rather than predictions, and individual responses vary significantly.
*These timelines summarize patterns reported across selected published studies and observational cohorts. They are not specific predictions, and they do not represent expected outcomes for any individual patient. Individual experiences vary considerably, and some patients may experience minimal or no improvement. Evidence for MSC therapy in Parkinson’s disease remains preliminary, and larger controlled clinical trials are needed to validate these observations. All timelines should be interpreted as exploratory and non-confirmatory.
Meet some of the patients who have trusted our team with their regenerative medicine treatment.
Systematic review and meta-analysis evaluating safety, efficacy, and clinical outcomes of cell-based therapies in Parkinson’s disease.
View published study
Systematic review analyzing therapeutic potential, mechanisms, and clinical applications of mesenchymal stem cell therapies for neurological diseases including Parkinson’s.
View published study
Scientific review discussing translational challenges, clinical considerations, and therapeutic mechanisms of cell-based treatments for Parkinson’s disease.
View published study
Regenerative Medicine Specialist | Stem Cells Transplant Institute
Dr. Heidy Chaves is a dedicated physician specializing in regenerative medicine. She earned her medical degree from Universidad de Ciencias Médicas (UCIMED) and pursued advanced training in aesthetic medicine in Spain and hair transplantation in Greece. She holds multiple international certifications in regenerative therapies and life support.
San José, Costa Rica
info@stemcellstransplantinstitute.com
+1 888 785-4170
